Drug Law Enforcement Strategies provides an authoritative, insider's perspective on the intricacies of drug crimes, investigations, and trials. Featuring law enforcement officials from around the country, this book guides the reader through the latest trends in the narcotics arenaincluding new drugs entering the market, the medical marijuana controversy, and the role of technology in investigationswhile analyzing how these issues are impacting procedures. These skilled authors highlight proven methods for embarking on an investigation, creating drug-specific case strategies, working with informants, going undercover, and setting short- and long-term goals for an investigation. Looking at the investigator's role in bringing a drug case to court, they also explain how to supply effective evidence, work successfully with prosecutors, and anticipate questions from defense attorneys. Additionally, these leaders reveal their strategies for collaborating with other agencies, training investigators, and coping with shrinking budgets and limited manpower. The different niches represented and the breadth of perspectives presented enable readers to get inside some of the great legal minds of today, as these experienced officers offer up their thoughts on the keys to success within this ever-evolving field.

We’re losing the “war on drugs”—but the fight isn’t over yet Federal Narcotics Laws and the War on Drugs examines our current anti-drug programs and policies, explains why they have failed, and presents a plan to fix them. Author Thomas C. Rowe, who has been educating college students on recreational drug use for nearly 30 years, exposes the truth about anti-drug programs he believes were conceived in ignorance of the drugs themselves and motivated by racial/cultural bias. This powerful book advocates a shift in federal spending to move funds away from the failed elements of the “war on drugs” toward policies with a more realistic chance to succeed—the drug courts, education, and effective treatment. Common myths and misconceptions about drugs have produced anti-drug programs that don’t work, won’t work, and waste millions of dollars. Federal Narcotics Laws and the War on Drugs looks at how—and why—this has happened and what can be done to correct it. The book is divided into “How did we get into this mess?” which details the history of anti-narcotic legislation, how drug agencies evolved, and the role played by Harry Anslinger, Commissioner of the United States Bureau of Narcotics from 1930 to 1962; “What works and what doesn’t work,” which looks at the failure of interdiction efforts and the negative consequences that have resulted with a particular focus on the problems of prisons balanced against the drug court system; and a third section that serves as an overview of various recreational drugs, considers arguments for and against drug legalization, and offers suggestions for more effective methods than our current system allows. Federal Narcotics Laws and the War on Drugs also examines: the creation of the Federal Bureau of Narcotics current regulations and structures current federal sentencing guidelines current state of the courts and the prison system mandatory sentencing and what judges think interdiction for heroin, cocaine and crack cocaine, and marijuana early education efforts the DARE program drug use trends drug treatment models the debate over legalization Federal Narcotics Laws and the War on Drugs also includes several appendices of federal budget figures, cocaine and heroin purity and price, and federal bureau of prisons statistics. This unique book is required reading for anyone concerned about the drug problem in the United States and what is—and isn’t—being done to correct it.

It's a national epidemic and an international conspiracy. Drugs have infested our society with a vengeance, making the drug enforcement agent a central figure in the war on drugs. International training teams of the U.S. Drug Enforcement Administration (DEA) have traditionally taught the special skills required by all drug agents. Until now, there

Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.